Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 mutations in urinary bladder cancer.

P Berggren1, G Steineck, J Adolfsson

  • 1Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden.

British Journal of Cancer
|June 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Risk of hernia formation after radical prostatectomy: a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial.

Hernia : the journal of hernias and abdominal wall surgery·2022
Same author

Measurement of the Cross Sections of Ξ_{c}^{0} and Ξ_{c}^{+} Baryons and of the Branching-Fraction Ratio BR(Ξ_{c}^{0}→Ξ^{-}e^{+}ν_{e})/BR(Ξ_{c}^{0}→Ξ^{-}π^{+}) in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2022
Same author

Measurement of Prompt D^{0}, Λ_{c}^{+}, and Σ_{c}^{0,++}(2455) Production in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2022
Same author

Λ_{c}^{+} Production and Baryon-to-Meson Ratios in pp and p-Pb Collisions at sqrt[s_{NN}]=5.02  TeV at the LHC.

Physical review letters·2021
Same author

Experimental Evidence for an Attractive p-ϕ Interaction.

Physical review letters·2021
Same author

Multiharmonic Correlations of Different Flow Amplitudes in Pb-Pb Collisions at sqrt[s_{NN}]=2.76  TeV.

Physical review letters·2021

p53 gene mutations were found in 14% of urinary bladder neoplasms. Loss of heterozygosity (LOH) suggests other p53 inactivation mechanisms, particularly in distinguishing tumor grades.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor gene plays a critical role in preventing cancer development.
  • Mutations and alterations in p53 function are frequently observed in various cancers, including urinary bladder neoplasms.
  • Understanding p53 alterations is crucial for classifying tumor malignancy and predicting patient outcomes.

Purpose of the Study:

  • To investigate the frequency and patterns of p53 gene mutations and loss of heterozygosity (LOH) in urinary bladder neoplasms.
  • To correlate p53 alterations with tumor grade and stage.
  • To explore alternative mechanisms of p53 inactivation beyond direct mutation.

Main Methods:

  • Screening for mutations in exons 5-8 of the p53 gene in 189 patients with urinary bladder neoplasms.

Related Experiment Videos

  • Analysis of loss of heterozygosity (LOH) using p53 exogenic (CA)n repeat and p53 intragenic (AAAAT)n repeat markers.
  • Correlation of genetic findings with tumor characteristics (grade and stage).

    • Main Results:

    • p53 mutations were identified in 26 (14%) of 189 patients.
    • Only one mutation was found in a lowly malignant neoplasm (Ta, G1-G2a); the majority occurred in highly malignant tumors (G2b-G4 or >= T1).
    • 30% of samples showed LOH, and 31 samples (21%) exhibited LOH without detectable mutations, suggesting other p53 inactivation pathways.

    Conclusions:

    • Genetic events affecting p53 function appear to delineate a boundary between G2a and G2b tumors.
    • Moderately differentiated (G2) urinary bladder neoplasms are genetically heterogeneous.
    • These findings support reclassifying G2 tumors into either lowly or highly malignant categories based on genetic events affecting p53.